SpringerLink
Log in

Antiestrogen-estrogen receptor interactions

  • Chapter
Mammary Tumor Cell Cycle, Differentiation, and Metastasis

Part of the book series: Cancer Treatment and Research ((CTAR,volume 83))

Abstract

Estrogens function as mitogens primarily in the G1 phase of the cell cycle by recruiting cells into the cycle and by shortening the length of their G1 phase. Conversely, estrogen antagonists that inhibit cell proliferation reduce the proportion of cells in S phase [1]. The precise role of estrogen in cell growth and proliferation is poorly understood. Initially it was proposed that estrogens stimulate proliferation indirectly by increasing the production of growth factors such as transforming growth factor (TGF)- α [2] or reducing the secretion of growth inhibitory factors such as TGF-β [3,4]. Alternatively, since estrogens stimulate the expression of receptors for a number of growth factors, including those for insulin-like growth factor (IGF-I) and epidermal growth factor (EGF) [5,6], they might function by increasing the sensitivity of cells to growth factors produced either by tumor cells themselves or perhaps by surrounding stromal cells, thereby regulating cell proliferation by a paracrine mechanism [7].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Brunner N, Bronzert D, Vindelov LL, Rygaard K, Spang-Thomsen M, Lippman ME (1989) Effect on growth and cell cycle kinetics of estradiol and tamoxifen on MCF-7 human breast cancer cells grown in vitro and in nude mice. Cancer Res 49: 1515–1520.

    PubMed  CAS  Google Scholar 

  2. Bates SE, Davidson NE, Valverius EM, Dickson RB, Freter CE, Tam JP, Kulow JE, Lippman ME, Salomon S (1988) Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer, its regulation by estrogen and its possible functional significance. Mol Endocrinol 2: 543–545.

    Article  PubMed  CAS  Google Scholar 

  3. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB (1987) Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417–428.

    Article  PubMed  CAS  Google Scholar 

  4. Roberts AB, Sporn MB (1992) Mechanistic interrelationships between two superfamilies: The steroid/retinod receptors and transforming growth factor-β. In Cancer Surveys, Vol 14. MG Parker (ed). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, pp 205–220.

    Google Scholar 

  5. Stewart AJ, Johnson MD, May FEB, Westley BR (1990) Role of insulin-like growth factors and the Type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265: 21172–21178.

    PubMed  CAS  Google Scholar 

  6. Berthois Y, Dong XF, Martin PM (1989) Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF7. Biochem Biophys Res Commun 159: 126–131.

    Article  PubMed  CAS  Google Scholar 

  7. Clarke R, Dickson RB, Lippman ME (1991) The role of steroid hormones and growth factors in the control of normal and malignant breast. In Nuclear Hormone Receptors. M Parker (ed). London: Academic Press, pp 297–319.

    Google Scholar 

  8. Wilding G, Lippman ME, Gelmann EP (1988) Effects of steroid hormones and peptide growth factors on proto-oncogene c-fos expression in human breast cancer cells. Cancer Res 48: 802–805.

    PubMed  CAS  Google Scholar 

  9. Dubik D, Dembinski TC, Shiu RPC (1987) Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 47: 6517–6521.

    PubMed  CAS  Google Scholar 

  10. Musgrove EA, Sutherland RL (1994) Cell cycle control by steroid hormones. In Seminars in Cancer Biology, Vol 5. M Parker (ed). London: Academic Press, pp 381–389.

    Google Scholar 

  11. Martinez E, Wahli W (1991) Characterization of hormone response elements. In Nuclear Hormone Receptors. Molecular Mechanisms, Cellular Functions, Clinical Abnormalities. MG Parker (ed). London: Academic Press, pp 125–154.

    Google Scholar 

  12. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR (1990) Transcription factor interactions: Selectros of positive or negative regulation from a single DNA element. Science 249: 1266–1272.

    Article  PubMed  CAS  Google Scholar 

  13. Martinez E, Wahli W (1989) Cooperative binding of estrogen receptor to imperfect estrogen-responsive DNA elements correlates with their synergistic hormone-dependent enhancer activity. EMBO J 8: 3781–91.

    PubMed  CAS  Google Scholar 

  14. Pratt WB (1993) Role of heat-shock proteins in steroid receptor function. In Steroid Hormone Action. MG Parker (ed). Oxford: IRL Press, pp 64–93.

    Google Scholar 

  15. Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106: 1377–1388.

    PubMed  CAS  Google Scholar 

  16. Fawell SE, Lees JA, White R, Parker MG (1990) Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60: 953–962.

    Article  PubMed  CAS  Google Scholar 

  17. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P (1989) The human estrogen receptor has two independent nonacidic trascriptional activation functions. Cell 59: 477–487.

    Article  PubMed  CAS  Google Scholar 

  18. Lees JA, Fawell SE, Parker MG (1989) Identification of two transcativation domains in the mouse oestrogen receptor. Nucleic Acids Res 17: 5477–5488.

    Article  PubMed  CAS  Google Scholar 

  19. Webster NJG, Green S, ** JR, Chambon P (1988) The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54: 199–207.

    Article  PubMed  CAS  Google Scholar 

  20. Ptashne M (1988) How eukaryotic transcriptional activators work. Nature 335: 683–689.

    Article  PubMed  CAS  Google Scholar 

  21. Mitchell PJ, Tjian R (1989) Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins. Science 245: 371–378.

    Article  PubMed  CAS  Google Scholar 

  22. Ing NH, Beekman JM, Tsai SY, Tsai M-J, O’Malley BW (1992) Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J Biol Chem 267: 17617–17623.

    PubMed  CAS  Google Scholar 

  23. Sadovsky Y, Webb P, Lopez G, Baxter JD, Cavailles V, Parker MG, Kushner PJ (1994) Transcriptional activators differ in their response to overexpression of TBP. Mol Cell Biol, in press.

    Google Scholar 

  24. Jacq X, Brou C, Lutz Y, Davidson I, Chambon P, Tora L (1994) Human TAF11 30 is present in a distrinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell 79: 107–117.

    Article  PubMed  CAS  Google Scholar 

  25. Cavaillès V, Dauvois S, Danielian PS, Parker MG (1994) Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 91: 10009–10013.

    Article  PubMed  Google Scholar 

  26. Philips A, Chalbos D, Rochefort H (1993) Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J Biol Chem 268: 14103–14108.

    PubMed  CAS  Google Scholar 

  27. Jordan VC (1984) Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36: 245–276.

    PubMed  CAS  Google Scholar 

  28. Bowler J, Lilley TJ, Pittam JD, Wakelling AE (1989) Novel steroidal pure antiestrogens. Steroids 54: 71–99.

    Article  PubMed  CAS  Google Scholar 

  29. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867–3873.

    PubMed  CAS  Google Scholar 

  30. Danielian PS, White R, Lees JA, Parker MG (1992) Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11: 1025–1033.

    PubMed  CAS  Google Scholar 

  31. Pakdel F, Katzenellenbogen BS (1992) Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 267: 3429–3437.

    PubMed  CAS  Google Scholar 

  32. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai M-J, O’Malley BW (1992) Hormone and anti-hormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267: 19513–19520.

    PubMed  CAS  Google Scholar 

  33. Kumar V, Chambon P (1988) The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55: 145–156.

    Article  PubMed  CAS  Google Scholar 

  34. Berry M, Metzger D, Chambon P (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.EMBO J 9: 2811–2818.

    PubMed  CAS  Google Scholar 

  35. Brown M, Sharp PA (1990) Human estrogen receptor forms multiple protein-DNA complexes. J Biol Chem 265: 11238–11243.

    PubMed  CAS  Google Scholar 

  36. Meyer M-E, Pornon A, Ji J, Bocquel M-T, Chambon P, Gronemeyer H (1990). Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. EMBO J 9: 3923–3932.

    PubMed  CAS  Google Scholar 

  37. Chalbos D, Philips A, Rochefort H (1994) Genomic cross-talk between the estrogen receptor and growth factor regulatory pathways in estrogen target tissues. In Seminars in Cancer Biology, Vol 5. M Parker (ed). London: Academic Press, pp 361–368.

    Google Scholar 

  38. Dauvois S, Danielian PS, White R, Parker MG (1992) Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037–4041.

    Article  PubMed  CAS  Google Scholar 

  39. Arbuckle ND, Dauvois S, Parker MG (1992) Effects of antioestrogens on the DNA binding activity of oestrogen receptors in vitro. Nucleic Acids Res 20: 3839–3844.

    Article  PubMed  CAS  Google Scholar 

  40. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG (1990) Inhibition of estrogen receptor-DNA binding by the ‘pure’ antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 87: 6883–6887.

    Article  PubMed  CAS  Google Scholar 

  41. Pham TA, Elliston JF, Nawaz Z, McDonnell DP, Tsai MJ, O’Malley BW (1991) Antiestrogen can establish nonproductive receptor complexes and alter chromatin structure at target enhancers. Proc Natl Acad Sci USA 88: 3125–3129.

    Article  PubMed  CAS  Google Scholar 

  42. Reese JC, Katzenellenbogen BS (1992) Examination of the DNA-binding ability of estrogen receptor in whole cells: Implications for hormone-dependent transactivation and the actions of antiestrogens. Mol Cell Biol 12: 4531–4538.

    PubMed  CAS  Google Scholar 

  43. Zysk JR, Johnson B, Ozenberger BA, Bingham B, Gorski J (1995) Selective uptake of estrogenic compunds by Saccharomyces cerevisiae: A mechanism for antiestrogen resistance in yeast expressing the mammalian estrogen receptor. Endocrinology 136: 1323–1326.

    Article  PubMed  CAS  Google Scholar 

  44. Bentley A, Fentiman IS, Rubens RD, Cuzick J, Crossley E, Durrand K, Harris A, Clarke M, Collins R, Godwin J, Gray R, Greaves E, Harwood C, Mead G, Peto R, Wheatley K (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Part 2. Lancet 339: 71–85.

    Google Scholar 

  45. Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O’Malley BW, McGuire WL (1991) Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51: 105–109.

    PubMed  CAS  Google Scholar 

  46. Daffada AAI, Johnston SRD, Smith IE, Detre S, King N, Dowsett M (1995) Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone/receptor/pS2 status in human breast cancer. Cancer Res 55: 288–293.

    PubMed  CAS  Google Scholar 

  47. Karnik PS, Kulkarni S, Liu XP, Budd GT, Gukowski RM (1994) Estrogen-receptor mutations in tamoxifen-resistant breast-cancer. Cancer Res 54: 349–353.

    PubMed  CAS  Google Scholar 

  48. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG (1993) Identification of residues in the estrogen receptor which confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7: 232–240.

    Article  PubMed  CAS  Google Scholar 

  49. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W (1995) Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA, in press.

    Google Scholar 

  50. Chalbos D, Philips A, Galtier F, Rochefort H (1993) Synthetic antiestrogens modulate induction of pS2 and Cathepsin D messenger ribonucleic acid by growth factors and adenosine 3’,5’-monophosphate in MCF-7 cells. Endocrinology 133: 571–576.

    Article  PubMed  CAS  Google Scholar 

  51. Fujimoto NaK BS (1994) Alteration in the agonist/antagonist balance of antiestrogens by activiation of protein kinase A signalling pathways in breast cancer cells: Antiestrogen-selectivity and promoter-dependence. Mol Endocrinol 8: 296–304.

    Article  PubMed  CAS  Google Scholar 

  52. Smith CL, Conneely OM, O’Malley BW (1993) Modulation of ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc Natl Acad Sci USA 90: 6120–6124.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Malcolm G. Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Cell Biology and Pharmacology, Lombardi Cancer Center, The Research Building, 3970 Reservoir Road, 20007, Washington, DC, USA

    Robert B. Dickson PHD

  2. Departments of Medicine and Pharmacology, Lombardi Cancer Center, The Research Building, 20007, 3970 Reservoir Road, Washington, CD, USA

    Marc E. Lippman MD

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

Parker, M.G. (1996). Antiestrogen-estrogen receptor interactions. In: Dickson, R.B., Lippman, M.E. (eds) Mammary Tumor Cell Cycle, Differentiation, and Metastasis. Cancer Treatment and Research, vol 83. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1259-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1259-8_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8536-6

  • Online ISBN: 978-1-4613-1259-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation